139 related articles for article (PubMed ID: 21834810)
1. Thymus and activation-regulated chemokine in different stages of mycosis fungoides: tissue and serum levels.
Abou El-Ela M; El-Rifae Ael-A; Fawzi M; Abdel Hay R; Gohary Y; Shaker O
Australas J Dermatol; 2011 Aug; 52(3):167-71. PubMed ID: 21834810
[TBL] [Abstract][Full Text] [Related]
2. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides.
Kakinuma T; Sugaya M; Nakamura K; Kaneko F; Wakugawa M; Matsushima K; Tamaki K
J Am Acad Dermatol; 2003 Jan; 48(1):23-30. PubMed ID: 12522366
[TBL] [Abstract][Full Text] [Related]
3. Treatment with IFN-gamma increases serum levels of Th1 chemokines and decreases those of Th2 chemokines in patients with mycosis fungoides.
Hino R; Shimauchi T; Tokura Y
J Dermatol Sci; 2005 Jun; 38(3):189-95. PubMed ID: 15927812
[TBL] [Abstract][Full Text] [Related]
4. Presence of circulating CCR10+ T cells and elevated serum CTACK/CCL27 in the early stage of mycosis fungoides.
Fujita Y; Abe R; Sasaki M; Honda A; Furuichi M; Asano Y; Norisugi O; Shimizu T; Shimizu H
Clin Cancer Res; 2006 May; 12(9):2670-5. PubMed ID: 16675558
[TBL] [Abstract][Full Text] [Related]
5. Alterations of serum Th1 and Th2 chemokines by combination therapy of interferon-gamma and narrowband UVB in patients with mycosis fungoides.
Shimauchi T; Sugita K; Nishio D; Isoda H; Abe S; Yamada Y; Hino R; Ogata M; Kabashima K; Tokura Y
J Dermatol Sci; 2008 Jun; 50(3):217-25. PubMed ID: 18243665
[TBL] [Abstract][Full Text] [Related]
6. Mycosis fungoides--a review of the management of 28 patients and of the recent literature.
Lenane P; Powell FC; O'Keane C; Dervan P; O'Sullivan D; Bourke E; O'Loughlin S
Int J Dermatol; 2007 Jan; 46(1):19-26. PubMed ID: 17214715
[TBL] [Abstract][Full Text] [Related]
7. Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity.
Kakinuma T; Nakamura K; Wakugawa M; Mitsui H; Tada Y; Saeki H; Torii H; Asahina A; Onai N; Matsushima K; Tamaki K
J Allergy Clin Immunol; 2001 Mar; 107(3):535-41. PubMed ID: 11240957
[TBL] [Abstract][Full Text] [Related]
8. Mycosis fungoides with focal CD 30 transformation in an adolescent.
Romero M; Haney M; Desantis E; Zlotoff B
Pediatr Dermatol; 2008; 25(5):565-8. PubMed ID: 18950403
[TBL] [Abstract][Full Text] [Related]
9. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT
Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308
[TBL] [Abstract][Full Text] [Related]
10. Mycosis fungoides associated with B-cell malignancies.
Barzilai A; Trau H; David M; Feinmesser M; Bergman R; Shpiro D; Schiby G; Rosenblatt K; Or R; Hodak E
Br J Dermatol; 2006 Aug; 155(2):379-86. PubMed ID: 16882178
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical study of the expression of matrix metalloproteinase-9 in skin lesions of mycosis fungoides.
Rasheed H; Tolba Fawzi MM; Abdel-Halim MR; Eissa AM; Mohammed Salem N; Mahfouz S
Am J Dermatopathol; 2010 Apr; 32(2):162-9. PubMed ID: 20051814
[TBL] [Abstract][Full Text] [Related]
12. Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases.
Saeki H; Tamaki K
J Dermatol Sci; 2006 Aug; 43(2):75-84. PubMed ID: 16859899
[TBL] [Abstract][Full Text] [Related]
13. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.
López-Lerma I; Estrach MT
J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537
[TBL] [Abstract][Full Text] [Related]
14. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
15. The nature of mycosis fungoides.
Lawrence CM; Marks JM; Burridge A; Moss C; Ive FA; McGibbon D; Parker S; Coburn P; Shuster S
Q J Med; 1986 Mar; 58(227):281-93. PubMed ID: 3737871
[TBL] [Abstract][Full Text] [Related]
16. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides.
Kallinich T; Muche JM; Qin S; Sterry W; Audring H; Kroczek RA
J Invest Dermatol; 2003 Nov; 121(5):1045-52. PubMed ID: 14708605
[TBL] [Abstract][Full Text] [Related]
17. Depressed lymphokine activated killer cell activity in mycosis fungoides. A possible marker for aggressive disease.
Wood NL; Kitces EN; Blaylock WK
Arch Dermatol; 1990 Jul; 126(7):907-13. PubMed ID: 2360838
[TBL] [Abstract][Full Text] [Related]
18. Serum measurement of thymus and activation-regulated chemokine/CCL17 in children with atopic dermatitis: elevated normal levels in infancy and age-specific analysis in atopic dermatitis.
Fujisawa T; Nagao M; Hiraguchi Y; Katsumata H; Nishimori H; Iguchi K; Kato Y; Higashiura M; Ogawauchi I; Tamaki K
Pediatr Allergy Immunol; 2009 Nov; 20(7):633-41. PubMed ID: 19236603
[TBL] [Abstract][Full Text] [Related]
19. [Long term results of total skin electron beam therapy (TSEBT) in the treatment of mycosis fungoides].
Hagedorn M; Hasche E; Kober B; Sander CA
Hautarzt; 2003 Mar; 54(3):256-64. PubMed ID: 12634995
[TBL] [Abstract][Full Text] [Related]
20. Serum visfatin levels in patients with atopic dermatitis and cutaneous T-cell lymphoma.
Suga H; Sugaya M; Miyagaki T; Kawaguchi M; Morimura S; Kai H; Kagami S; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Eur J Dermatol; 2013; 23(5):629-35. PubMed ID: 24001451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
